Demographics, disease duration, and serologic profile among 2300 patients with SSc evaluated 1990–2009.
| Characteristic | Age at Onset < 65 Yrs, n = 2084 | Age at Onset ≥ 65 Yrs, n = 216 | p |
|---|---|---|---|
| Women, n (%) | 1725 (83) | 184 (85) | 0.369 |
| African American, n (%) | 379 (18) | 24 (11) | 0.040 |
| Limited subtype disease, n (%) | 1302 (62) | 147 (68) | 0.108 |
| Smoking status, current or former§ | 992 (48) | 105 (50) | 0.601 |
| Median no. visits to JHSC, range | 3 (1, 28) | 2 (1, 19) | < 0.001 |
| Mean followup from first visit to JHSC among patients with > 1 visit§§ (yrs, ± SD) | 5 ± 4 | 4 ± 3 | < 0.001 |
| SSc duration, mean ± SD | |||
| Disease duration (yrs) at time of first visit to JHSC | 6 ± 8 | 2 ± 3 | < 0.001 |
| Duration (yrs) of RP at time of first visit to JHSC† | 9 ± 10 | 8 ± 13 | 0.4113 |
| Age of RP onset, yrs† | 40 ± 13 | 65 ± 13 | < 0.001 |
| Age at first non-RP symptoms, yrs | 43 ± 12 | 71 ± 5 | < 0.001 |
| Years from RP onset to first non-RP SSc symptom† | 3 ± 8 | 6 ± 13 | < 0.001 |
| Years from first non-RP SSc symptom to diagnosis of SSc by physician†† | 2 ± 5 | 0.5 ± 2.4 | < 0.001 |
| Serology, n/total analyzed (%) | |||
| ANA | 1259/1306 (96) | 120/124 (97) | 0.831 |
| Antitopoisomerase I | 277/1175 (23) | 18/107 (17) | 0.112 |
| Anticentromere | 348/1288 (27) | 50/119 (42) | 0.001 |
| Anti-U1RNP | 102/1084 (9) | 3/99 (3) | 0.033 |
↵§ Data analyzed from 2272 individuals with data recorded regarding smoking status.
↵§§ Data analyzed from 1521 individuals with > 1 visit to JHSC.
↵† Data analyzed from 2227 individuals with a reported date of onset for RP.
↵†† Data analyzed from 2291 individuals with a reported date of diagnosis by a physician. SSc: systemic sclerosis (scleroderma); JHSC: Johns Hopkins Scleroderma Center; RP: Raynaud’s phenomenon; ANA: anti-nuclear antibody.